# Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT03964753** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 202 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nab-paclitaxel and Cisplatin
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT03964753
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-24
- **Primary completion:** 2026-06-24
- **Final completion:** 2026-12-24
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03964753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03964753, "Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03964753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*